Two Draft Guidances Set Up FDA’s Plans To Gather Postmarket Data
The guidance documents outline the statutory authority the US FDA has in requiring postmarket surveillance reports and studies, the real-world evidence it plans to ask for from sponsors, and administrative details that may be expected.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty guidance documents have been posted on the tracker since its last update.
A new document from the IMDRF outlines the conditions for when postmarket clinical follow-up studies may be necessary, but underscores they have to conform to their local regulatory regimes.
The lawsuit against Kendall Patient Recovery accuses the company of intentionally ignoring decades of data warning against risks posed by ethylene oxide, causing harm to communities around its facility.